| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6095232 | Gastroenterology | 2014 | 27 Pages |
Abstract
In a phase 2 trial, EPA-E had no significant effect on the histologic features of NASH. EPA-E reduced subjects' levels of triglyceride compared with placebo, without any increase in serious adverse events. Clinicaltrials.gov Number: 01154985.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Arun J. Sanyal, Manal F. Abdelmalek, Ayako Suzuki, Oscar W. Cummings, Mario Chojkier, EPE-A Study Group EPE-A Study Group,